Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05844982 · ClinicalTrials.gov registry record · Phase 3
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
A Phase 3 study of Visual Impairment and Radiation Retinopathy, sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05844982 is a Phase 3 study of Visual Impairment and Radiation Retinopathy that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 600 participants, above the 159-participant average among 7 other Visual Impairment trials with a reported enrollment target (277% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05844982, a Phase 3 study of Visual Impairment and Radiation Retinopathy, is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Conditions Studied
Interventions
- DRUG Faricimab
- DRUG fluocinolone acetonide
Study Locations (20)
Pennsylvania
- Retina-Vitreous Consultants, Inc. - Monroeville
- Wills Eye Hospital - Philadelphia
- Pittsburgh Clinical Trial Consortium - Sewickley
Illinois
- Northwestern Memorial Group - Chicago
- IL Eye and Ear Infirmary-University of Illinois at Chicago - Chicago
Michigan
- Foundation for Vision Research and Retina Specialists of Michigan, P.C. - Grand Rapids
- Associated Retinal Consultants, P.C. - Royal Oak
Texas
- Retina Consultants of Texas, PA - Bellaire
- UT Southwestern Medical Center - Dallas
California
- Byers Eye Institute at Stanford University - Palo Alto
Connecticut
- Retina Consultants - Manchester
Florida
- Retina Associates of Florida, LLC - Tampa
Indiana
- Midwest Eye Institute - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2029-12-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05844982
The ClinicalTrials.gov registry entry for NCT05844982 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 159-participant average among 7 other Visual Impairment trials with a reported enrollment target (277% higher). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Visual Impairment appearing as the primary indexed condition, and to 2 interventions - of which Faricimab is the first listed.
NCT05844982 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Pennsylvania, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT05844982 about?
NCT05844982 is a clinical study titled "Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy". This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
What is the current status of trial NCT05844982?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-11-21. Estimated completion is 2029-12-26.
What conditions does trial NCT05844982 study?
This clinical trial studies the following conditions: Visual Impairment, Radiation Retinopathy.
What interventions are being tested in trial NCT05844982?
The interventions under investigation include: Faricimab (DRUG), fluocinolone acetonide (DRUG).
Who is sponsoring clinical trial NCT05844982?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05844982 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Visual Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of a Multi-sensory Rehabilitation Program for People With Ultra Low Vision
RECRUITING · NA
-
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
RECRUITING · NA
-
Improving Visual Field Deficits With Noninvasive Brain Stimulation
RECRUITING · NA
-
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss
RECRUITING · NA
-
Nonvisual Foot Inspection for People With Visual Impairment
COMPLETED · NA
-
SmartHMD for Improved Mobility
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.